Want to see ADMA full AI Analyst Report?
ADMA Stock Chart & Stats
$11.01
-$0.24(-1.31%)
At close: 4:00 PM EST
$11.01
-$0.24(-1.31%)
Day’s Range― - ―
52-Week Range$7.21 - $20.46
Previous CloseN/A
Volume407.39K
Average Volume (3M)3.27M
Market Cap
$2.04B
Enterprise Value$2.23K
Total Cash (Recent Filing)$138.15M
Total Debt (Recent Filing)$204.41M
Price to Earnings (P/E)12.6
Beta0.87
Next Earnings
Aug 12, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.69
Shares Outstanding231,772,720
10 Day Avg. Volume2,198,878
30 Day Avg. Volume3,271,640
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)9.11
Price to Sales (P/S)8.52
P/FCF Ratio156.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.67Price Target Upside69.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.81
Revenue Forecast (FY)$534.89M
Bulls Say, Bears Say
Bulls Say
ASCENIV Revenue GrowthSustained, double-digit ASCENIV growth reflects durable clinical adoption and new patient starts, diversifying ADMA away from commodity IG sales. Structural demand for a differentiated, patented IVIG product supports recurring revenue, stronger mix, and longer-term pricing and reimbursement leverage.
Margin ExpansionA marked shift to higher-margin ASCENIV and yield-enhanced manufacturing drove gross margin expansion, demonstrating sustainable earnings quality. Higher gross margins support durable free cash flow, reinvestment in pipeline (SG-001) and strategic flexibility even if standard IG pricing softens.
Cash Generation & LiquidityConsistent operating cash generation and low pro forma leverage provide structural financial resilience. Strong cash flow funds R&D, manufacturing scale, opportunistic buybacks and buffers against distributor volatility, reducing refinancing risk and enabling strategic investments over the next 2–6 months.
Bears Say
BIVIGAM Revenue DeclineA steep, structural decline in BIVIGAM sales reduces product diversification and places greater earnings dependence on ASCENIV. Persistent distributor ordering disruption and share loss in standard IG can depress top-line durability and magnify single-product and channel concentration risk over the medium term.
Competitive Pricing PressureSustained ASP erosion from aggressive competitor discounting is a structural headwind for standard IG economics. Compression of realized prices forces higher rebates and promotional spend, undermining margin sustainability for commodity IG products and pressuring near-term revenue recovery.
Guidance Withdrawal & UncertaintyRemoval of longer-term guidance signals meaningful uncertainty in market dynamics and ordering patterns. This reduces visibility for capital allocation and may delay strategic investments; sustained unpredictability in distribution channels can impede durable planning and investor confidence.
ADMA Biologics News
ADMA FAQ
What was ADMA Biologics Inc’s price range in the past 12 months?
ADMA Biologics Inc lowest stock price was $7.21 and its highest was $20.46 in the past 12 months.
What is ADMA Biologics Inc’s market cap?
ADMA Biologics Inc’s market cap is $2.04B.
When is ADMA Biologics Inc’s upcoming earnings report date?
ADMA Biologics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 24 days.
How were ADMA Biologics Inc’s earnings last quarter?
ADMA Biologics Inc released its earnings results on May 06, 2026. The company reported $0.171 earnings per share for the quarter, missing the consensus estimate of $0.193 by -$0.022.
Is ADMA Biologics Inc overvalued?
According to Wall Street analysts ADMA Biologics Inc’s price is currently Undervalued.
Does ADMA Biologics Inc pay dividends?
ADMA Biologics Inc does not currently pay dividends.
What is ADMA Biologics Inc’s EPS estimate?
ADMA Biologics Inc’s EPS estimate is 0.17.
How many shares outstanding does ADMA Biologics Inc have?
ADMA Biologics Inc has 231,772,720 shares outstanding.
What happened to ADMA Biologics Inc’s price movement after its last earnings report?
ADMA Biologics Inc reported an EPS of $0.171 in its last earnings report, missing expectations of $0.193. Following the earnings report the stock price went down -15.972%.
Which hedge fund is a major shareholder of ADMA Biologics Inc?
Currently, no hedge funds are holding shares in ADMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ADMA Biologics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.67 (69.54% Upside)
$18.67 (69.54% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $250.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.48%
12-Months-Change
Fundamentals
Return on Equity
38.97%
Trailing 12-Months
Asset Growth
30.28%
Trailing 12-Months
Company Description
ADMA Biologics Inc
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
ADMA Stock 12 Month Forecast
Average Price Target
$18.67
▲(69.54% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Protagonist Therapeutics
―
Immunovant
―
MoonLake Immunotherapeutics
―
―
Ownership Overview
3.36% Insiders
25.89% Mutual Funds
0.05% Other Institutional Investors
38.87% Public Companies and
Individual Investors